S1 Biopharma downsizes IPO; Medgenics raising $21M;

@FierceBiotech: Woodford's investment strategy may help change the global biotech scene. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Fledgling biotech upstart blends cutting-edge cancer immunotherapy strategies -- BeneVir. Article | Follow @JohnCFierce

@DamianFierce: It's almost as if Italian authorities don't care about biotech traders. More | Follow @DamianFierce

> New York-based S1 Biopharma has whittled down its IPO plans and now expects to offer 1.8 million shares at $12 to $14 a share. The biotech is working on a therapy for female sexual dysfunction. Story

> Philadelphia-based Medgenics ($MEDG) priced 5,125,000 shares in its underwritten public offering at $4.10 per share. The company plans to raise $21 million. Release

Medical Device News

@FierceMedDev: Congress considering bill to limit FDA regulation of EHRs, clinical decision support software. Story | Follow @FierceMedDev

@VarunSaxena2: RT @FierceMedDev: From FierceDrugDelivery: Survey raises the question: Do patients really know how to use drug delivery devices? Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: LabCorp and CareDx call it quits on partnership to develop lupus test. FierceDiagnostics story | Follow @EmilyWFierce

> Opponents of FDA's LDT regulations lawyer up, get in combat mode. Story

> WSJ: Ankle replacements look to be the next thing. More

> Strategic investors LabCorp, Envision put $15M into remote patient monitoring startup Vivify. Article

Pharma News

@FiercePharma: Merck KGaA to power India plant with coconut and cashew shells. Story | Follow @FiercePharma

@CarlyHFierce: AstraZeneca's Almirall buy yields its first new drug--and now, AZ has to sell it. More | Follow @CarlyHFierce

> Who are the stars of personalized meds? Roche, Novartis and J&J. More

> Sanofi's pre-game show on Afrezza has MannKind followers chattering. Item

> Odds for a Pfizer-AZ matchup? All over the map, if you listen to analysts. Article

Drug Delivery News

> RNAi specialist Arrowhead reports loss of $58.7M in FY 2014. Item

> Singapore team combines cancer drugs, diagnostics in one biomarker nanoparticle. Report

> 'Hybrid' delivery vehicle gives DNA vaccines new potential. News

> Survey raises the question: Do patients really know how to use drug delivery devices? More

> Patients respond positively to Cynapsus film strip of apomorphine to combat Parkinson's. Article

Diagnostics News

> Curetis nabs $18M to support European Dx rollout, U.S. trial, possible IPO. News

> Illumina and bioMérieux to develop innovative sequencing system for infectious diseases. Article

> Indian startup develops low-cost, portable Dx for developing countries. Story

> LabCorp and CareDx call it quits on partnership to develop lupus test. Report

> Illumina teams up with Broad Institute, USAID for Ebola tracking. Item

Pharma Marketing News

> Who are the stars of personalized medicine? Roche, Novartis and J&J. Article

> From GPS inhalers to Jawbone data-gathering, some digital pharma inspiration. Story

> MannKind fans and critics line up for Sanofi's Afrezza pre-game show. More

> Ipsen on a hiring binge in U.S. to prep for new Somatuline marketing push. Story

> AstraZeneca's Almirall buy yields its first new drug--and now, AZ has to sell it. Article

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.